Tri‐substituted 1,3,5‐triazine‐based analogs as effective HIV‐1 non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A systematic review
Drug Development Research · 2024
DOI: 10.1002/ddr.22154 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Drug Development Research, 2024. Verfasst von Zebabanu Khalifa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Government College, Daman (Affiliated to Veer Narmad South Gujarat University, Surat), Daman, India. Hauptthemen laut MEDLINE: Reverse Transcriptase Inhibitors, Triazines, HIV-1, Anti-HIV Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: IPR-UGC Section, Veer Narmad South Gujarat University, Udhna-Magdalla Road, Surat-395007.
Abstract (Originalsprache)
Non‐nucleoside reverse transcriptase inhibitors (NNRTIs) have significantly impacted the HIV‐1 wild‐type due to their high specificity and superior potency. As well as different combinations of NNRTIs have been used on clinically approved combining highly active antiretroviral therapy (HAART) to resist the growth of HIV‐1 and decrease the mortality rate of HIV/AIDS. Although the feeble strength against the drug‐resistant mutant strains and the long‐term damaging effects have been reducing the effectiveness of HAART, it could be a crucial challenge to develop novel Anti‐HIV leads with a vital mode of action and the least side effects. The extensive chemical reactivity and the diverse chemotherapeutic applications of the 1,3,5‐triazine have provided a wide scope of research in medicinal chemistry via a structural modification. In this review, we focused on the Anti‐HIV profile of the tri‐substituted s ‐triazine derivatives with structure‐based features and also discussed the active mode of action to evaluate the significant findings. The tri‐substituted 1,3,5‐triazine derivatives have been found more promising to inhibit the growth of the drug‐sensitive and drug‐resistant variants of HIV‐1, especially HIV‐1 wild‐type, HIV‐1 K103N/Y181C, and HIV‐1 Tyr181Cys. It has been observed that these derivatives have interacted with the enzyme protein residues via a significant ‐ interaction and hydrogen bonding to resist the proliferation of the viral genomes. Further, the SAR and the active binding modes are critically described and highlight the role of structural variations with functional groups along with the binding affinity of targeted enzymes, which may be beneficial for rational drug discovery to develop highly dynamic Anti‐HIV agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Government College, Daman (Affiliated to Veer Narmad South Gujarat University, Surat), Daman, India.
ORCID-Profile: Amit B Patel
Förderung
- IPR-UGC Section, Veer Narmad South Gujarat University, Udhna-Magdalla Road, Surat-395007
Zitieren
APA
Khalifa, Z., & Patel, A. B. (2024). Tri‐substituted 1,3,5‐triazine‐based analogs as effective HIV‐1 non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A systematic review. Drug Development Research. https://doi.org/10.1002/ddr.22154
Vancouver
Khalifa Z, Patel AB. Tri‐substituted 1,3,5‐triazine‐based analogs as effective HIV‐1 non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A systematic review. Drug Development Research. 2024. doi:10.1002/ddr.22154
BibTeX
@article{Khalifa2024,
author = {Khalifa, Zebabanu and Patel, Amit B},
title = {Tri‐substituted 1,3,5‐triazine‐based analogs as effective HIV‐1 non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A systematic review},
journal = {Drug Development Research},
year = {2024},
doi = {10.1002/ddr.22154}
}
EUVIMED